EMA Drops Req’s for Testing Untreated Patients in Hemophilia

The European Medicines Agency revised two guidelines on the development and labeling of factor VIII products used to treat hemophilia A, removing requirements for sponsors to conduct clinical trials in previously untreated patients.
Source: International Pharmaceutical Regulatory Monitor